Pharmacogenomic and Pharmacometabolomic Biomarkers of the Efficacy and Safety of Antidepressants: Focus on Selective Serotonin Reuptake Inhibitors

被引：0
作者：
A. E. Gareeva [1 ]
L. S. Borodina [2 ]
S. A. Pozdnyakov [3 ]
I. F. Timerbulatov [4 ]
机构：
[1] Institute of Biochemistry and Genetics, Ufa Federal Research Center, Russian Academy of Sciences, Ufa
[2] Kemerovo State University, Kemerovo
[3] Russian Medical Academy of Continuous Professional Education, Russian Ministry of Health, Moscow
[4] Republican Narcology Dispenser No. 1, Ministry of Health of the Republic of Bashkortostan, Ufa
[5] Moscow Scientific and Applied Narcology Center, Moscow City Health Department, Moscow
[6] Usoltsev Central Clinical Psychiatric Hospital, Moscow
[7] Russian Medical University, Russian Ministry of Health, Moscow
来源：
Neuroscience and Behavioral Physiology | 2024年 / 54卷 / 8期
关键词：
antidepressants; pharmacogenomics; pharmacometabolomics; selective serotonin reuptake inhibitors;
D O I：
10.1007/s11055-024-01716-5
中图分类号：
学科分类号：
摘要：
The efficacy and safety of psychopharmacotherapy with antidepressants is of great medical importance. The search for clinical and biological predictors for the selection of optimal psychopharmacotherapy with antidepressants is under active investigation throughout the world. Most studies address the search for associations between polymorphic variants of genes and the efficacy and safety of therapy. However, data on patients’ genetic polymorphisms are often insufficient for predicting the efficacy and safety of a drug. Contemporary research on the personalization of pharmacotherapy should include not only genetic, but also phenotypic biomarkers. This is important because genotyping, for example, cannot accurately predict the real metabolic activity of an isoenzyme. Successful treatment of depression remains a complex task; between-individual differences in responses to antidepressants are common. About half of patients with depressive disorders do not respond to the first attempt at antidepressant therapy. Serious side effects in pharmacotherapy with antidepressants and discontinuation of treatment due to intolerance are associated with lack of therapeutic efficacy. This review presents results from the latest studies of “omics” biomarkers of the efficacy and safety of antidepressants. © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024.
引用
收藏
页码：1205 / 1214
页数：9
相关论文
共 86 条
  • [1] Tansey K.E., Guipponi M., Hu X., Et al., Contribution of common genetic variants to antidepressant response, Biol. Psychiatry, 73, 7, pp. 679-682, (2013)
  • [2] Campos A.I., Byrne E.M., Mitchell B.L., Et al., Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of 9500 participants of the Australian Genetics of Depression Study, Pharmacogenomics J, 22, 2, pp. 130-135, (2022)
  • [3] Kessler R.C., van Loo H.M., Wardenaar K.J., Et al., Using patient self-reports to study heterogeneity of treatment effects in major depressive disorder, Epidemiol. Psychiatr. Sci, 26, 1, pp. 22-36, (2017)
  • [4] Roughan W.H., Campos A.I., Garcia-Marin L.M., Et al., Comorbid chronic pain and depression: Shared risk factors and differential antidepressant effectiveness, Front. Psychiatry, 12, (2021)
  • [5] Campos A.I., Mulcahy A., Thorp J.G., Et al., Understanding genetic risk factors for common side effects of antidepressant medications, Commun. Med (Lond.), 1, 45, (2021)
  • [6] Braten L.S., Haslemo T., Jukic M.M., Et al., Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients, Neuropsychopharmacology, 45, 3, pp. 570-576, (2020)
  • [7] Brunoni A.R., Carracedo A., Amigo O.M., Et al., Association of BDNF, HTR2A, TPH1, SLC6A4, and COMT polymorphisms with tDCS and escitalopram efficacy: ancillary analysis of a double-blind, placebo-controlled trial, Braz. J. Psychiatry, 42, 2, pp. 128-135, (2020)
  • [8] Stein D.J., Craske M.G., Rothbaum B.O., Et al., The clinical characterization of the adult patient with an anxiety or related disorder aimed at personalization of management, World Psychiatry, 20, 3, pp. 336-356, (2021)
  • [9] Porcelli S., Fabbri C., Serretti A., Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy, Eur. Neuropsychopharmacol, 22, 4, pp. 239-258, (2012)
  • [10] Zou Z., Huang Y., Wang J., Et al., The association between serotonin-related gene polymorphisms and susceptibility and early sertraline response in patients with panic disorder”, BMC Psychiatry, 20, No, 1, (2020)
123456789